A Chinese medicinal compound for treating respiratory infectious diseases and its application

By adjusting the combination ratio and preparation method of Chinese medicine compound prescriptions, the prepared Chinese medicine compound prescription effectively solves the problems of poor efficacy, side effects, high cost and high recurrence rate of respiratory infectious diseases in the prior art, achieving low cost and high efficiency , non-toxic therapeutic effects significantly improve the cure rate and safety.

CN117281871BActive Publication Date: 2024-11-05SHANGHAI HAICUI PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310529209.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-11
Publication Date
2024-11-05
Estimated Expiration
2043-05-11

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention provides a Chinese medicine compound for treating respiratory infectious diseases, which is made of the following raw materials in parts by weight: 7-11 parts of honeysuckle, 7-11 parts of schizonepeta, 10-14 parts of astragalus, 7-11 parts of patchouli, 7-11 parts of siler, 7-11 parts of siler, 7-11 parts of isatis root, 7-11 parts of platycodon, 13-17 parts of rhizoma phragmites, and 4-8 parts of liquorice. The present invention also provides the use of the Chinese medicine composition. Its advantages are: the Chinese medicine composition has clear distinction between monarch and minister, proper adjuvant, cold and warm, clearing and tonifying, lung and defense treatment, dispersing and tonifying, tonifying and sparse, opposites complement each other, focusing on penetrating and dispersing evil spirits, benefiting the defense and consolidating the exterior, and playing the effects of dispersing wind and clearing heat, strengthening the body and consolidating the exterior.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The invention relates to a Chinese medicinal compound for treating respiratory infectious diseases and its application, in particular to a Chinese patent medicine prepared with Chinese herbal medicine as raw materials. [Background technology]

[0002] Respiratory infectious diseases refer to infectious diseases caused by pathogens invading the human body's nasal cavity, throat, trachea and bronchus. From ancient times to the present, humans have encountered countless respiratory infectious diseases, some of which are particularly serious and have had a huge impact on human production and life.

[0003] Chinese patent CN201610812905.8 discloses a Chinese medicine composition for treating exogenous fever and its preparation method. The Chinese medicine is made of the following raw materials in weight ratio: 10-25g of honeysuckle, 10-32g of dandelion, 10-18g of isatis indigotica, 10-16g of kudzu root, 10-32g of isatis root, 4-12g of red peony root, 3-12g of bupleurum, 3-10g of scutellaria, 5-12g of gentiana macrophylla, 3-12g of schizonepeta, 9-16g of lophatherum gracile, 5-12g of radish seed, 3-12g of platycodon, 3-12g of bitter almond, 3-12g of bombyx batryticatus, 5-12g of patchouli, 6-15g of anemarrhena, 3-8g of calamus, 3-12g of curcuma, and 6-16g of forsythia.

[0004] Shanghai Expert Consensus on Traditional Chinese Medicine Diagnosis and Treatment of Novel Coronavirus Infection (Spring 2022 Edition), Shanghai Journal of Traditional Chinese Medicine, 2022, 56(7): 5-6. The Jingyin Gubiao Formula Therapy for the treatment of asymptomatic infection is disclosed. The formula is composed of honeysuckle, schizonepeta, astragalus, saposhnikovia, patchouli, isatis root, platycodon, reed root, stir-fried atractylodes, and raw licorice. This article was published by the applicant earlier and did not disclose the dosage of the drug. Traditional Chinese Medicine JingYinGuBiao Formula TherapyImproves the Negative Conversion Rate of SARS-CoV2 in Patients with MildCOVID-19. Int J Biol Sci. 2022; 18(15): 5641–5652, which was also published by the applicant earlier. The article discloses the drug composition and dosage. However, the present application is an optimization of the number of medicinal flavors and dosages of the previously disclosed compositions by the inventors in strict accordance with the traditional theories of Chinese medicine through prescription and drug compatibility. The stir-fried Atractylodes macrocephala is removed from the prescription, and the dosages of Platycodon grandiflorum and Licorice are also changed. The optimized prescription is rigorous and novel, and the results of clinical and experimental studies show that the pharmaceutical composition has a definite therapeutic effect on respiratory infectious diseases, with low cost, no toxic side effects, short course of treatment, rapid effect, high cure rate, and basically no recurrence after recovery. [Summary of the invention]

[0005] The purpose of the present invention is to provide a Chinese medicine compound for treating respiratory infectious diseases in view of the deficiencies in the prior art.

[0006] Another object of the present invention is to provide a use of the above-mentioned medicine.

[0007] To achieve the above object, the technical solution adopted by the present invention is:

[0008] A traditional Chinese medicine compound for treating respiratory infectious diseases is prepared from the following raw materials in parts by weight: 7-11 parts of honeysuckle, 7-11 parts of schizonepeta, 10-14 parts of astragalus, 7-11 parts of patchouli, 7-11 parts of siler, 7-11 parts of isatis root, 7-11 parts of platycodon, 13-17 parts of reed root and 4-8 parts of liquorice.

[0009] Preferably, the traditional Chinese medicine composition is made of the following raw materials in parts by weight: 8-10 parts of honeysuckle, 8-10 parts of schizonepeta, 11-13 parts of astragalus, 8-10 parts of patchouli, 8-10 parts of siler, 8-10 parts of isatis root, 8-10 parts of platycodon, 14-16 parts of reed root, and 5-7 parts of licorice.

[0010] More preferably, the Chinese medicine composition is made of the following raw materials in parts by weight: 9 parts of honeysuckle, 9 parts of schizonepeta, 12 parts of astragalus, 9 parts of patchouli, 9 parts of siler, 9 parts of isatis root, 9 parts of platycodon, 15 parts of reed root, and 6 parts of liquorice.

[0011] Preferably, the Chinese medicine composition is in the form of granules, decoctions, tablets, capsules, oral liquids, mixtures or syrups.

[0012] To achieve the above second purpose, the technical solution adopted by the present invention is:

[0013] Use of any of the above-mentioned traditional Chinese medicine compositions in the preparation of drugs for treating respiratory infectious diseases.

[0014] The advantages of the present invention are:

[0015] In the Chinese medicine compound, honeysuckle has a fragrant smell and is light and dispersing. It can not only dispel wind and relieve the exterior, clear away heat and detoxify, but also avoid filth and clear turbidity. It is the main medicine. Schizonepeta is pungent and slightly warm, dispersing the exterior and dispersing evil, helping the main medicine to open the skin and fur to expel evil, and can clear the upper part of the body. Astragalus is sweet and warm, which can replenish the qi of the lungs and spleen internally, benefit the defense to consolidate the exterior, and help the dispersing power of schizonepeta and silver externally, and strengthen the body to eliminate evil. Patchouli is pungent, warm and aromatic, which can disperse the exterior evil externally and eliminate dampness and turbidity internally. It is pungent and dispersing but not harsh, slightly warm but not hot, and has the effect of aromatic warding off filth. Schizonepeta, Astragalus, and Patchouli are all assistant medicines. Saposhnikovia is sweet, slow, slightly warm but not harsh, and is a general medicine for wind disease. It is good at dispersing wind and relieving the exterior. It is used together with Schizonepeta to enhance the power of dispersing the exterior evil. When Astragalus is combined with Saposhnikovia, it consolidates the exterior without retaining evil; when Saposhnikovia is combined with Astragalus, it eliminates evil without hurting the body. Isatis root is good at detoxifying, relieving sore throat and dispersing knots, Platycodon grandiflorum is pungent and bitter, and can open up the lung qi and benefit the chest, diaphragm and throat, and help clear the upper part of the body. Phragmites australis is often used together with wind-heat dispersing drugs such as Schizonepeta tenuifolia and Lonicera japonica. It can clear the qi, divide the Wei and divide the evil heat, and eliminate restlessness and produce body fluid without the disadvantage of lingering evil. Saposhnikovia divaricata, Isatis root, Platycodon grandiflorum and Phragmites australis are adjuvants. Licorice is slightly cold in nature, and combined with Platycodon grandiflorum, it can clear heat, relieve sore throat and relieve pain, and can also reconcile the properties of the medicine, making it a guiding drug. The above medicines have clear monarch and ministerial functions, and the adjuvant is appropriate. They are used together with cold and warm, and both clearing and tonifying are taken into account. The lung and Wei are treated at the same time, and the dispersing and tonifying are combined, and the tonifying contains the dispersing. The opposites complement each other, and the emphasis is on dispersing evil qi, benefiting the Wei and consolidating the exterior, and playing the effects of dispersing wind and heat, and strengthening the body and consolidating the exterior. [Specific implementation method]

[0016] The specific implementation modes provided by the present invention are described in detail below.

[0017] Example 1 Chinese medicine composition for treating respiratory infectious diseases (I)

[0018] 9 parts of honeysuckle, 9 parts of schizonepeta, 12 parts of astragalus, 9 parts of patchouli, 9 parts of siler, 9 parts of isatis root, 9 parts of platycodon, 15 parts of reed root, and 6 parts of liquorice.

[0019] Example 2 Chinese medicine composition for treating respiratory infectious diseases (II)

[0020] 9 parts of honeysuckle, 8 parts of schizonepeta, 13 parts of astragalus, 7 parts of patchouli, 11 parts of siler, 9 parts of isatis root, 8 parts of platycodon, 16 parts of reed root, and 4 parts of liquorice.

[0021] Example 3 Chinese medicine composition for treating respiratory infectious diseases (III)

[0022] 8 parts of honeysuckle, 10 parts of schizonepeta, 10 parts of astragalus, 11 parts of patchouli, 9 parts of siler, 8 parts of isatis root, 10 parts of platycodon, 13 parts of rhizoma phragmites, and 8 parts of liquorice.

[0023] Example 4 Chinese medicine composition for treating respiratory infectious diseases (IV)

[0024] 10 parts of honeysuckle, 7 parts of schizonepeta, 14 parts of astragalus, 9 parts of patchouli, 8 parts of siler, 10 parts of isatis root, 7 parts of platycodon, 17 parts of reed root, and 6 parts of liquorice.

[0025] Example 5 Chinese medicine composition for treating respiratory infectious diseases (V)

[0026] 7 parts of honeysuckle, 11 parts of schizonepeta, 12 parts of astragalus, 8 parts of patchouli, 10 parts of siler, 7 parts of isatis root, 11 parts of platycodon, 15 parts of reed root, and 5 parts of liquorice.

[0027] Example 6 Chinese medicine composition for treating respiratory infectious diseases (VI)

[0028] 11 parts of honeysuckle, 9 parts of schizonepeta, 11 parts of astragalus, 10 parts of patchouli, 7 parts of siler, 11 parts of isatis root, 9 parts of platycodon, 14 parts of reed root, and 7 parts of liquorice.

[0029] Example 7 Chinese medicine composition for treating respiratory infectious diseases (VII)

[0030] 9 parts of honeysuckle, 10 parts of schizonepeta, 10 parts of astragalus, 11 parts of patchouli, 9 parts of siler, 8 parts of isatis root, 10 parts of platycodon, 13 parts of rhizoma phragmites, and 8 parts of liquorice.

[0031] Example 8 Chinese medicine composition for treating respiratory infectious diseases (VIII)

[0032] 8 parts of honeysuckle, 7 parts of schizonepeta, 14 parts of astragalus, 9 parts of patchouli, 8 parts of siler, 10 parts of isatis root, 7 parts of platycodon, 17 parts of reed root, and 6 parts of liquorice.

[0033] Example 9 Chinese medicine composition for treating respiratory infectious diseases (IX)

[0034] 10 parts of honeysuckle, 11 parts of schizonepeta, 12 parts of astragalus, 8 parts of patchouli, 10 parts of siler, 7 parts of isatis root, 11 parts of platycodon, 15 parts of rhizoma phragmites, and 5 parts of liquorice.

[0035] Example 10 Chinese medicine composition for treating respiratory infectious diseases (X)

[0036] 7 parts of honeysuckle, 9 parts of schizonepeta, 11 parts of astragalus, 10 parts of patchouli, 7 parts of siler, 11 parts of isatis root, 9 parts of platycodon, 14 parts of reed root, and 7 parts of liquorice.

[0037] Example 11 Chinese medicine composition for treating respiratory infectious diseases (XI)

[0038] 11 parts of honeysuckle, 8 parts of schizonepeta, 13 parts of astragalus, 7 parts of patchouli, 11 parts of siler, 9 parts of isatis root, 8 parts of platycodon, 16 parts of reed root, and 4 parts of liquorice.

[0039] Example 12 Preparation of Chinese medicine composition tablets / capsules for treating respiratory infectious diseases

[0040] Take any one of the Chinese medicine compositions described in Examples 1-11, add 9-11 times the amount of water, decoct for 2-3.5 hours, and filter out the medicinal juice. Add 9 times the amount of water again, decoct for 2.5 hours, filter out the medicinal juice, combine the two decoctions, let stand, filter out the supernatant, concentrate, cool, add 3 times the amount of alcohol of the concentrate, stir and precipitate overnight. Take the supernatant, concentrate to a thick extract; add pharmaceutical excipients, vacuum dry, crush and granulate, press into tablets or fill in capsules.

[0041] Example 13 Preparation of Chinese medicine composition granules for treating respiratory infectious diseases

[0042] Take the Chinese medicine composition described in any one of Examples 1-11, add 8-10 times the amount of water, decoct for 3 hours, and filter out the juice. Add 10 times the amount of water again, decoct for 2.5 hours, filter out the juice, combine the two decoctions, let stand, filter out the supernatant, concentrate, cool, add 2 times the amount of alcohol of the concentrate, stir and precipitate overnight. Take the supernatant, concentrate to a thick extract; add appropriate pharmaceutical excipients, granulate, dry, granulate, and pack 15g / bag.

[0043] Example 14 Preparation of Chinese medicine composition mixture / oral liquid / syrup for treating respiratory infectious diseases

[0044] Take the Chinese medicine composition described in any one of Examples 1-11, add 8-11 times the amount of water, decoct for 3 hours, and filter out the juice. Add 8 times the amount of water again, decoct for 3 hours, filter out the juice, combine the two decoctions, let stand, filter out the supernatant, concentrate, cool, add 3.5 times the amount of alcohol of the concentrate, stir and precipitate overnight. Take the supernatant, concentrate to a thick extract; add appropriate pharmaceutical excipients to prepare a mixture, oral liquid or syrup.

[0045] Example 15 Animal Experiment

[0046] 1. Experimental Materials

[0047] 1.1 Drugs and reagents

[0048] Treatment group 1 preparation: 9 parts of honeysuckle, 9 parts of schizonepeta, 12 parts of astragalus, 9 parts of patchouli, 9 parts of siler, 9 parts of isatis root, 9 parts of platycodon, 15 parts of reed root, 6 parts of liquorice;

[0049] Preparation of treatment group 2: 10 parts of honeysuckle, 7 parts of schizonepeta, 14 parts of astragalus, 9 parts of patchouli, 8 parts of siler, 10 parts of isatis root, 7 parts of platycodon, 17 parts of reed root, 6 parts of liquorice;

[0050] Preparation of control group 1: 9 parts of honeysuckle, 9 parts of schizonepeta, 12 parts of astragalus, 9 parts of patchouli, 9 parts of siler, 9 parts of isatis root, 6 parts of platycodon, 15 parts of reed root, 9 parts of honey bran fried atractylodes, 9 parts of liquorice tablets (compound before optimization);

[0051] Preparation of control group 2: 10 parts of honeysuckle, 7 parts of cinnamon twig, 14 parts of astragalus, 9 parts of perilla, 8 parts of siler, 10 parts of isatis root, 7 parts of platycodon, 17 parts of anemarrhena, and 6 parts of liquorice;

[0052] Blank group: normal saline;

[0053] Model group: normal saline.

[0054] 1.2 Animals

[0055] Sixty BALB / c mice, half male and half female, weighing 20±2g, were purchased from Shanghai Xipu-Bikai Experimental Animal Co., Ltd.

[0056] 1.3 Main instruments and reagents

[0057] Heraleus-Fresco21 micro-refrigerated centrifuge (Thermo Fisher Scientific, Germany);

[0058] SARS-COV-2 protein (Guangzhou Paizhen Biotechnology Co., Ltd.); mouse IL-2 ELISA kit, mouse TNF-α ELISA kit, and mouse IFN-γ ELISA kit were all purchased from Shanghai ELISA Biotechnology Co., Ltd.

[0059] 2. Methods and Results

[0060] 2.1 Grouping

[0061] 60 mice were divided into model group, treatment group 1, treatment group 2, control group 1, control group 2 and blank group, with 10 mice in each group.

[0062] 2.2 Modeling and drug administration

[0063] Except for the 10 mice in the blank group, the remaining 50 mice were intranasally inoculated with SARS-CoV-2 virus at a dose of 25 μL / mouse. At 25°C, a light-dark cycle was maintained under the lighting conditions of 8:00-20:00, and the mice were fed with laboratory standard feed and had normal drinking water. The symptoms of the mice were observed after 24 hours. If there were symptoms such as shortness of breath, dyspnea, irritability, and hair loss, the model was successfully established. Finally, there were 45 mice with successful modeling, including 8 mice in treatment group 1, 10 mice in treatment group 2, 9 mice in control group 1, 9 mice in control group 2, and 9 mice in model group. On the day when the model was judged to be successful, intragastric administration began. The mice in the treatment group and the control group were administered with a concentration of 18 mg / kg according to their body weight, and the administration volume was 5 ml / kg. The model group and the blank group were administered with an equal volume of saline for 14 consecutive days. After the administration, blood was collected from the eyeballs, left to stand overnight at 4°C, and serum was collected by centrifugation at 3000 r / min for 10 minutes. The operation was carried out according to the instructions of the kit to calculate the concentrations of IL-2, IFN-γ, and TNF-α in serum.

[0064] 2.3 Statistical methods

[0065] SPSS 25.0 software was used for statistical processing of data. Measurement data were expressed as (x±s), and those that met normal distribution were analyzed by t test.

[0066] 2.4 Results

[0067] 2.4.1 Concentrations of IL-2, IFN-γ, and TNF-α in the serum of mice in each group

[0068] Compared with the blank group mice, the levels of 1L-2, IFN-γ and TNF-α in the model group mice were significantly increased; compared with the model group, the levels of 1L-2, IFN-γ and TNF-α in the treatment group and the control group were significantly decreased (p < 0.01), (p < 0.05); compared with the control group, the levels of 1L-2, IFN-γ and TNF-α in the treatment group were significantly decreased (p < 0.05), as shown in Table 1.

[0069] Table 1 Comparison of TNF-α, IL-1β and IL-2 levels in serum of mice in each group

[0070]

[0071] Note: *Compared with the blank group, p<0.01; #Compared with the model group, (p<0.01, p<0.05); &Compared with the control group, p<0.05.

[0072] Example 16 Clinical Trial

[0073] 1. Materials and methods

[0074] 1.1 Clinical Data

[0075] The cases in this study were collected from the Shuguang Hospital COVID-19 patients from April 6 to May 20, 2022. infection A total of 393 patients were divided into a treatment group of 262 and a control group of 131.

[0076] 1.2 Diagnostic criteria

[0077] Western medicine diagnostic standards: The diagnosis of asymptomatic infection with the new coronavirus is formulated in accordance with the "Diagnosis and Treatment Plan for Pneumonia Infected by the New Coronavirus (Trial Ninth Edition)" and the "Prevention and Control Plan for Pneumonia Infected by the New Coronavirus (Eighth Edition)". If the nucleic acid test for the new coronavirus infection is positive, the clinical classification standards are as follows:

[0078] 1. Lightweight

[0079] The clinical symptoms were mild and no pneumonia was found in the imaging studies.

[0080] (II) Ordinary type

[0081] With the above clinical manifestations, imaging studies may show pneumonia.

[0082] (III) Heavy

[0083] Adults who meet any of the following criteria:

[0084] 1) Shortness of breath, RR ≥ 30 times / min;

[0085] 2) At rest, oxygen saturation is ≤93% when breathing air;

[0086] 3) Arterial oxygen partial pressure (PaO2) / inhaled oxygen concentration (FiO2) ≤ 300 mmHg (1 mmHg = 0.133 kPa);

[0087] In high-altitude areas (over 1000 meters above sea level), PaO2 / FiO2 should be corrected according to the following formula: PaO2 / FiO2×[760 / atmospheric pressure (mmHg)].

[0088] 4) The clinical symptoms progressively worsen, and lung imaging shows that the lesions have significantly progressed by >50% within 24 to 48 hours.

[0089] The child meets any of the following criteria:

[0090] 1) Continuous high fever for more than 3 days;

[0091] 2) Shortness of breath (<2 months old, RR ≥ 60 times / min; 2-12 months old, RR ≥ 50 times / min; 1-5 years old, RR ≥ 40 times / min; >5 years old, RR ≥ 30 times / min), excluding the effects of fever and crying;

[0092] 3) In the resting state, oxygen saturation is ≤93% when breathing air;

[0093] 4) assisted breathing (nasal flaring, three-recess sign);

[0094] 5) Drowsiness and convulsions occur;

[0095] 6) Refusing to eat or having difficulty feeding, and signs of dehydration.

[0096] (IV) Critical

[0097] Those who meet one of the following conditions:

[0098] 1) Respiratory failure occurs and mechanical ventilation is required;

[0099] 2) shock occurs;

[0100] 3) Patients with other organ failure require ICU monitoring and treatment.

[0101] 1.3 Inclusion criteria

[0102] Candidates must meet all of the following criteria to be selected:

[0103] (1) Aged 18-65 (inclusive), regardless of gender;

[0104] (2) There is a new crown infection Close contact and secondary close contact standards: nucleic acid test results are positive and clinical classification is mild;

[0105] (3) Volunteer to participate in this trial and sign the written informed consent.

[0106] 1.4 Exclusion criteria

[0107] If any of the following criteria are met, then the applicant is excluded:

[0108] (1) Combined with influenza, other pneumonia, purulent tonsillitis, acute tracheobronchitis, pulmonary tuberculosis, primary ciliary dyskinesia syndrome, and other acute nasal diseases (such as allergic rhinitis, acute and chronic rhinitis, acute and chronic sinusitis, etc.);

[0109] (2) During the current course of illness, the patient had received other oral medications for the disease, such as cold medicines, antiviral drugs, antibiotics, traditional Chinese medicine, etc. before the visit;

[0110] (3) Accompanied by gastrointestinal discomfort symptoms such as acute and chronic diarrhea;

[0111] (4) Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and blood systems, such as viral hepatitis, hemophilia, unstable controlled / combined with serious complications of diabetes, mental illness, etc.;

[0112] (5) Women who are pregnant or planning to become pregnant, breastfeeding women, patients of childbearing age who are unable or unwilling to take adequate contraceptive measures during the trial, or whose spouses are unwilling to take contraceptive measures;

[0113] (6) Allergic constitution, such as a history of allergy to more than two drugs or foods, or known allergy to any component of the study drug;

[0114] (7) Participated or is currently participating in other drug clinical trials within 3 months;

[0115] (8) Other diseases or conditions that, according to the investigator's judgment, reduce the likelihood of enrollment or complicate enrollment, such as pregnancy, frequent changes in work environment, unstable living environment, etc., which are likely to cause loss to follow-up.

[0116] 1.5 Treatment

[0117] Control group: one-tenth dose of Jingyin Gubiao Optimized Formula;

[0118] Treatment group: Intervention with Jingyin Gubiao optimized prescription.

[0119] 1.6 Statistical analysis

[0120] SPSS 25.0 software was used for statistical analysis of the data in this study. Frequency and composition ratio were used to describe the count data, and χ 2 If the measurement data conformed to the normal distribution, the two independent sample t test was used for inter-group comparison, and the paired t test was used for intra-group comparison; if it did not conform to the normal distribution, the rank sum test was used. P < 0.05 was considered statistically significant.

[0121] 1.7 Observation indicators

[0122] (1) Main efficacy indicators:

[0123] Changes in Ct values ​​of N gene and ORF gene in novel coronavirus nucleic acid detection.

[0124] Nucleic acid tests were performed on days 0, 3, and 6 respectively.

[0125] Fluorescence quantitative PCR method was used to determine the Ct value of the N gene and ORF gene of the novel coronavirus nucleic acid test. Negative: no Ct value or Ct value > 40. Positive: Ct value < 35. Ct value (cycle threshold) refers to the Ct value of nucleic acid detection, that is, the number of cycles required for the PCR fluorescence signal to reach the threshold.

[0126] Qualitatively determine whether the nucleic acid has turned negative based on the Ct value and calculate the negative conversion rate.

[0127] (2) Secondary efficacy indicators:

[0128] ① Conversion rate to common type: The researchers counted the number of patients who turned into COVID-19 during the trial. infection Number of people of ordinary type;

[0129] ②Average time for nucleic acid test to turn negative: nucleic acid tests were performed on days 0, 3, and 6 respectively.

[0130] 1.8 Clinical efficacy evaluation methods

[0131] The nucleic acid negative conversion rate is expressed as a percentage, nucleic acid negative conversion rate = number of nucleic acid negative conversions / total number of enrolled people in the same group*100%.

[0132] 2. Results

[0133] 2.1 Comparison of nucleic acid negative conversion rate in each group at 3d and 6d after medication

[0134] On the third day after taking the Jingyin Gubiao Optimization Formula, the negative conversion rate of nucleic acid showed that the Jingyin Gubiao Optimization Formula was 34.7%, and the placebo control group (one-tenth of the dose of the Jingyin Gubiao Optimization Formula) was 19.8%. There was a statistical difference in the negative conversion rate between the experimental group and the placebo control group (p < 0.001). On the sixth day after taking the medicine, the negative conversion rate of nucleic acid showed that the Jingyin Gubiao Optimization Formula was 79.4%, and the placebo control group (one-tenth of the dose of the Jingyin Gubiao Optimization Formula) was 61.0%. There was a statistical difference in the negative conversion rate between the experimental group and the placebo control group (p < 0.001). See Table 2 and Table 3.

[0135] Table 2 Comparison of nucleic acid negative conversion rate within 3 days between the two groups [cases (%)]

[0136]

[0137] Table 3 Comparison of nucleic acid negative conversion rate within 6 days between the two groups [cases (%)]

[0138]

[0139] 3. Conclusion

[0140] After one course of intervention (6 days), the median time for the test group to turn negative was 4.89 days, which was lower than 6.31 days in the placebo control group (p < 0.05), and none of the cases included in the observation turned into severe cases. The Jingyin Gubiao Optimized Formula can shorten the time for nucleic acid to turn negative and speed up the discharge time for patients with mild new coronavirus.

[0141] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a Chinese medicine composition in the preparation of a drug for treating novel coronavirus infection, characterized in that: The medicine is prepared from the following raw materials in parts by weight: 9 parts of honeysuckle, 9 parts of schizonepeta, 12 parts of astragalus, 9 parts of patchouli, 9 parts of siler, 9 parts of isatis root, 9 parts of platycodon, 15 parts of reed root and 6 parts of liquorice.

2. The use according to claim 1, characterized in that: The medicine of the Chinese medicine composition is granules, decoctions, tablets, capsules, mixtures or syrups.